Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) CHOLESTYRAMINE-ODAN cholestyramine for oral suspension, USP light powder 4g x 30 sachets (Odan, Canada)
Section 19A approved medicine
(Approval lapsed) CHOLESTYRAMINE-ODAN cholestyramine for oral suspension, USP light powder 4g x 30 sachets (Odan, Canada)
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Phone
1300 788 261
Approved until
Status
Expired
Medicines in short supply/unavailable
QUESTRAN LITE colestyramine 850mg/g powder sachet - ARTG 11971
Indication(s)
1. Reduction of serum cholesterol levels and prevention of coronary heart disease. It is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoproteins). It may be useful to lower elevated cholesterol that occurs in patients with combined hypercholesterolemia and hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern.
2. Relief of pruritus associated with partial biliary obstruction. Patients with primary biliary cirrhosis may exhibit elevated serum cholesterol as part of their disease. When cholestyramine is used to treat the pruritus of partial biliary obstruction, it may lower serum cholesterol levels, produce no change, or cause rapid escape from a temporary lowering to pre-treatment levels or rebound.
3. Relief of diarrhoea following ileal resection or ileal disease (cholerrhoeic enteropathy).
Images
